Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study
Table 2
Clinical outcomes at 1 year††.
Endpoint
Treatment group
Control group
Unadjusted HR
Adjusted HR
valu
()‡‡
()‡‡
(95% CI)
(95% CI)
Primary endpoint
11 (2.7)
25 (6.2)
0.43 (0.21 to 0.87)
0.44 (0.21 to 0.92)
0.015
Death/MI
4 (1.0)
8 (2.0)
0.49 (0.15 to 1.64)
0.35 (0.09 to 1.33)
0.238
Revascularization
8 (2.0)
22 (5.4)
0.35 (0.16 to 0.80)
0.36 (0.16 to 0.82)
0.008
Secondary end point
14 (3.5)
35 (8.7)
0.39 (0.21 to 0.72)
0.37 (0.20 to 0.71)
0.002
Readmission for ACS
8 (2)
24 (5.9)
0.33 (0.15 to 0.72)
0.29 (0.13 to 0.65)
0.004
Stroke
3 (0.7)
6 (1.5)
0.49 (0.12 to 1.97)
0.69 (0.16 to 3.02)
0.307
Congestive HF
3 (0.7)
5 (1.2)
0.59 (0.14 to 2.48)
0.52 (0.12 to 2.36)
0.469
††Values are expressed as (%). ‡‡Kaplan-Meier estimate. P value derived from log-rank test.
